André Lieber, MD, PhD
The main objective of research in Dr. Lieber's laboratory is to develop new approaches for cancer therapy. The work is currently focused on several areas: (1) stem cell gene therapy for treatment of late-stage breast and ovarian cancer; (2) targeted genetic modification of hematopoietic stem cells and induced pluripotent stem cells; (3) enhancement of monoclonal antibody therapy of cancer by peptides that allow for opening of epithelial junctions or sensitization to complement killing; (4) adenovirus vector-mediated gene transfer into tumors to mediate oncolysis or stimulate anti-tumor immune responses; and (5) characterization of cancer stem cells, specifically their tumor-forming capacity. Dr. Lieber collaborates with Drs. Dichek and Russell.